Literature DB >> 6815155

Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas pulmonary infection in patients with cystic fibrosis.

J Levy, D Baran, J Klastersky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6815155     DOI： 10.1093/jac/10.3.227

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  10 in total

Review 1.  Advancing outcome measures for the new era of drug development in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Richard A Kronmal
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

2.  Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients.

Authors:  P Vic; S Ategbo; D Turck; M O Husson; E Tassin; G A Loeuille; A Deschildre; D Druon; J C Elian; C Arrouet-Lagandre; J P Farriaux
Journal:  Eur J Pediatr       Date:  1996-11       Impact factor: 3.183

3.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

Review 4.  Pharmacokinetics of antibiotics in cystic fibrosis patients with particular reference to the bronchopulmonary tree (review).

Authors:  E Bergogne-Berezin
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

5.  Quantification of amikacin in bronchial epithelial lining fluid in neonates.

Authors:  C Tayman; M N El-Attug; E Adams; A Van Schepdael; A Debeer; K Allegaert; A Smits
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

Review 6.  Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.

Authors:  Heather E Elphick; Alison Scott
Journal:  Cochrane Database Syst Rev       Date:  2016-12-01

7.  Potentiation of Aminoglycoside Activity in Pseudomonas aeruginosa by Targeting the AmgRS Envelope Stress-Responsive Two-Component System.

Authors:  Keith Poole; Christie Gilmour; Maya A Farha; Erin Mullen; Calvin Ho-Fung Lau; Eric D Brown
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 8.  How to manage Pseudomonas aeruginosa infections.

Authors:  Matteo Bassetti; Antonio Vena; Antony Croxatto; Elda Righi; Benoit Guery
Journal:  Drugs Context       Date:  2018-05-29

Review 9.  Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.

Authors:  Matthew N Hurley; Andrew P Prayle; Patrick Flume
Journal:  Cochrane Database Syst Rev       Date:  2015-07-30

10.  Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.

Authors:  Poppy Holland; Nikki Jahnke
Journal:  Cochrane Database Syst Rev       Date:  2021-06-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.